Avid Bioservices Inc (CDMO)

[Thurly]

Iwfal and ex,

bavi showed 43% ORR in an open-label, INDIAN NSCLC trial. In the ongoing, MULTICENTERED (inc. USA), open-label PIIb for 1st line NSCLC, the investigator reads recorded 25% ORR.

When it's said that Asians live longer, does that include India and would you think the drop in ORR was related to the shift to a mixed, as opposed to a oure Asian population in the two trials? In other words, would a shift of 18% be in the ballpark of the expected shift moving from pure Asian to a truly mixed population in such small trials?

Understood that we are looking at n=49 in the Indian, open-label trial and that the ability to assess may not permit strong conclusions given the limitations of the trials.